Key Takeaways
- Valero Energy (VLO) significantly surpassed Q2 2025 earnings expectations, reporting adjusted EPS of $2.28 against an estimated $1.72, and revenue of $29.89 billion compared to an estimated $26.97 billion.
- Pfizer (PFE) secured exclusive rights to develop the SSGJ-707 drug, a strategic move poised to expand its pharmaceutical portfolio and potentially strengthen its market position.
- China's Premier expressed willingness to broaden collaboration in trade, investment, and green technologies, while also emphasizing dialogue and negotiations to resolve disagreements.
- President Trump is scheduled to visit the Federal Reserve on Thursday, joining White House aides for a previously arranged tour.
Valero Energy (VLO) delivered a robust performance in its second-quarter 2025 earnings, significantly exceeding analyst expectations. The company reported an adjusted earnings per share (EPS) of $2.28, comfortably beating the estimated $1.72. Revenue also came in strong at $29.89 billion, surpassing the $26.97 billion estimate. Contributing to the strong results, Valero's refining margin per barrel reached $12.35, higher than the estimated $11.75.
In the pharmaceutical sector, Pfizer (PFE) announced it has received exclusive rights to develop the SSGJ-707 drug. This strategic acquisition is expected to expand Pfizer's pharmaceutical portfolio, indicating a continued focus on growth and innovation within its drug pipeline.
Geopolitical developments saw China's Premier articulate a clear stance on international relations. According to Xinhua, the Premier stated China's willingness to broaden collaboration in trade, investment, and green technologies. Concurrently, the Premier emphasized the importance of resolving disagreements and conflicts through proper dialogue and negotiations. These statements underscore China's dual approach of seeking economic cooperation while advocating for diplomatic solutions to international issues.
Domestically, President Trump is set to visit the Federal Reserve on Thursday. The visit will include White House aides and is part of a previously arranged tour of the institution. This visit comes at a time of ongoing economic discussions and could draw market attention regarding potential policy implications.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.